title: Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients.
abstract: BACKGROUND
  Facial lipoatrophy is a frequently reported condition associated with use of antiretroviral (ARV) drugs. Poly-L-lactic acid (PLLA) acid has been used to correct facial lipoatrophy in people with HIV since 2004 both in Europe and the United States. The objective of this study was to establish, in real life conditions and in a large sample, the safety of PLLA (New Fill®, Valeant US, Sinclair Pharma Paris, France) to correct facial lipoatrophy among HIV-positive patients.
  
  
  METHODS
  A longitudinal study was conducted between 2005 and 2008 in France. Data from 4,112 treatment courses (n = 4,112 patients) and 15,665 injections sessions (1 to 5 injection sessions per treatment course) were gathered by 200 physicians trained in the use of PLLA.
  
  
  RESULTS
  The average age of patients (88.3% males) treated for lipoatrophy was 47.1 ± 8.1 years (Mean ± SD); 91.2% of patients had been receiving ARV treatment for 10.9 (±4.2) years; CD4 T-cell count was 535 ± 266 cells/mm3. The duration of facial lipoatrophy was 5 ± 2.8 years and the severity was such that 47.3% of patients required five injection sessions of PLLA and 81.9% of the sessions required two vials of the preparation. The final visit, scheduled two months after the last injection session, was attended by 66.0% of patients (n = 2,713). 48 treatment courses (2.8%) were discontinued due to adverse events (AEs). The overall incidence of AEs per course was 18.8%. Immediate AEs, bleeding (3.4%), bruising (2.3%), pain (2.0%), redness at injection site (1.6%), and swelling of the face (0.7%), occurred in 15.4% of courses and 7.0% of sessions (usually during the first session). Non-immediate AEs, mainly nodules (5.7%), inflammation (0.7%), granuloma (0.3%), discolouration (0.2%), and skin hypertrophy (0.1%), occurred in 6.7% of courses. Non-immediate AEs occurred within a time ranging from 21 days (inflammation) to 101 days (granuloma) and all but three of the 13 cases of granuloma resolved. Product efficacy was rated satisfactory by 95% of the patients and physicians.
  
  
  CONCLUSIONS
  This study demonstrated, in real-life conditions and on a large sample, that PLLA injections were feasible, efficient, and safe when performed by trained physicians.
authors.affiliation: University Paris Diderot, Sorbonne Paris Cité, EA REMES, Patient Reported Outcomes Unit, Paris, & AP-HP, Bicêtre Hospital, Internal Medicine and Clinical Immunology, Le Kremlin-Bicêtre, Paris, France. duracinsky.m@gmail.com.
authors.forename: Martin
authors.initials: M
authors.lastname: Duracinsky
authors.forename: Pascale
authors.initials: P
authors.lastname: Leclercq
authors.forename: Susan
authors.initials: S
authors.lastname: Herrmann
authors.forename: Marie-Odile
authors.initials: MO
authors.lastname: Christen
authors.forename: Marc
authors.initials: M
authors.lastname: Dolivo
authors.forename: Cécile
authors.initials: C
authors.lastname: Goujard
authors.forename: Olivier
authors.initials: O
authors.lastname: Chassany
mesh_terms: D000328:Adult; D018791:CD4 Lymphocyte Count; D002482:Cellulose / Q000627:therapeutic use*; D005145:Face; D005260:Female; D005602:France; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy*; D006801:Humans; D019344:Lactic Acid / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008353:Mannitol / Q000627:therapeutic use*; D008875:Middle Aged; D011091:Polyesters; D011108:Polymers / Q000627:therapeutic use; D014481:United States
chemical_list: C482305:New-Fill; D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; D008353:Mannitol; C033616:poly(lactide); D002482:Cellulose